PVLA compared with ARQT: revenue, margins and what each company keeps, and the suppliers and customers both name

PVLAPalvella Therapeutics, Inc.

Mkt capRevenueRevenue

ARQTArcutis Biotherapeutics, Inc.

Mkt capRevenueRevenue

Compare

PVLAPalvella Therapeutics, Inc.

ARQTArcutis Biotherapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only PVLA 0

None

Shared 0

No disclosed counterparties: PVLA.

Only ARQT 5

AZNAstraZeneca ABsupplier

—Jiangsu Hengrui Medicineunlistedsupplier

—Hangzhou Zhongmei Huadong Pharmaceuticalunlistedcustomer

—Kowa Pharmaceuticals Americaunlistedcustomer

1 more · ARQT chain ›

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

PVLAPalvella Therapeutics, Inc.

174.90▲+11.51%· post 174.90

Mkt cap—Revenue—Revenue—

ARQTArcutis Biotherapeutics, Inc.

25.55▼−5.38%· post 25.56

ClosedNov 6 '26

Mkt cap$3.4BRevenue$144MQ3 FY26Revenue$376MFY25

Compare

ClosedNov 6 '26

PVLAPalvella Therapeutics, Inc.

ARQTArcutis Biotherapeutics, Inc.

174.90▲+11.51%post 174.90

Price

25.55▼−5.38%post 25.56

—

Mkt cap

$3.4B

—

Revenue

$144MQ3 FY26

—

Revenue

$376MFY25

PVLA174.90▲+11.51%vsARQT25.55▼−5.38%ClosedNov 6 '26